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Abstract
Background: Traditionally, patients at low risk and high risk of developing dental disease have been encouraged to
attend dental recall appointments at regular intervals of six months between appointments. The lack of evidence
for the effect that different recall intervals between dental check-ups have on patient outcomes, provider workload
and healthcare costs is causing considerable uncertainty for the profession and patients, despite the publication of
the NICE Guideline on dental recall. The need for primary research has been highlighted in the Health Technology
Assessment Group’s systematic review of routine dental check-ups, which found little evidence to support or refute
the practice of encouraging 6-monthly dental check-ups in adults. The more recent Cochrane review on recall
interval concluded there was insufficient evidence to draw any conclusions regarding the potential beneficial or
harmful effects of altering the recall interval between dental check-ups. There is therefore an urgent need to assess
the relative effectiveness and cost-benefit of different dental recall intervals in a robust, sufficiently powered
randomised control trial (RCT) in primary dental care.
Methods: This is a four year multi-centre, parallel-group, randomised controlled trial with blinded outcome assessment
based in dental primary care in the UK. Practitioners will recruit 2372 dentate adult patients. Patient participants will be
randomised to one of three groups: fixed-period six month recall, risk-based recall, or fixed-period twenty-four month
recall. Outcome data will be assessed through clinical examination, patient questionnaires and NHS databases. The
primary outcomes measure gingival inflammation/bleeding on probing and oral health-related quality of life.
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Discussion: INTERVAL will provide evidence for the most clinically-effective and cost-beneficial recall interval for
maintaining optimum oral health in dentate adults attending general dental practice.
Trial registration: ISRCTN95933794 (Date assigned 20/08/2008).
Keywords: Dental recall, Oral health, RCT, Primary care
Background
Traditionally, patients at low risk and high risk of developing
dental disease have been encouraged to attend dental recall
appointments at regular intervals of six months between ap-
pointments, with the logic of prevention and early detection
of disease [1]. The lack of evidence for the effect that differ-
ent recall intervals between dental check-ups have on pa-
tient outcomes, provider workload and healthcare costs is
causing considerable uncertainty for the profession and pa-
tients, particularly following the General Dental Council
guidance for team working responsibilities around recall in-
tervals [2] and despite the publication of the NICE Guide-
line [3]. The need for primary research has been highlighted
in the Health Technology Assessment Group’s systematic
review of routine dental check-ups [4], which found little
evidence to support or refute the practice of encouraging
6-monthly dental check-ups in adults. The more recent
Cochrane review on recall interval found only one trial,
which was assessed as having a high risk of bias, with 185
participants and concluded there was insufficient evidence
to draw any conclusions regarding the potential beneficial or
harmful effects of altering the recall interval between dental
check-ups [5]. The limited evidence from recent observa-
tional studies also supports the need for research. Evaluation
of the Canadian Non-Insured Health Benefits (NIHB) pro-
gram found clients with more ‘regular’ check-ups received a
standard pattern of service but incurred greater expenditure
than those with longer gaps between recalls [6]. Recent evi-
dence from the Dutch health system suggests an increase in
General Dentists applying an individualised recall interval
from 49% in 2000 to 61% in 2005 and that these dentists
provide more frequent periodontal screening than those
using a fixed recall interval [7].
Many Clinical Commissioning Groups (CCGs) in
England are now seeking to secure adherence to the
NICE recall interval guideline as part of their clinical
governance responsibilities when commissioning dental
primary care services. However, the lack of direct evi-
dence behind differing recall strategies complicates the
adoption process, while uncertainty remains within
CCGs and among dentists as to how best to implement
the guidance in practice.
There is therefore an urgent need to assess the relative
effectiveness and value for money of different dental re-
call intervals in a robust, sufficiently powered rando-
mised control trial (RCT) in primary dental care.
Trial aim
The aim of this study is to compare the effectiveness and
cost-benefit of dental check-ups at different recall inter-
vals (fixed-period six month recall, risk-based recall or
fixed-period 24 m recall) for maintaining optimum oral
health in dentate adults attending general dental practice.
Objectives
The primary objectives are to compare (1) gingival in-
flammation and (2) oral health-related quality of life
(OHRQoL) of dentate adults receiving a dental check-up
at different recall intervals over a four year period:
1. Fixed-period six month recall
2. Risk-based recall
3. Fixed-period 24 m recall
The secondary objectives are to compare the effect of the
three recall strategies on periodontal probing depths, dental
caries, calculus, preventive and interventive dental treatment,
patient anxiety, patient satisfaction with care, oral health
knowledge, attitudes and behaviours. The cost-effectiveness
and cost-benefit of the three recall strategies will also be
assessed as part of the economic evaluation.
Methods
This is a UK multi-centre, parallel-group, randomised
controlled trial with blinded outcome assessment. The
trial is set in Primary Dental Care, reflecting the setting
within which the vast majority of dentistry is delivered
in the UK.
Trial interventions
The trial interventions are three recall intervals – a
fixed-period extended 24 m recall interval, a
Risk-Variable-Adjusted-Length recall interval (Risk-based
recall) based on the NICE Guideline and a fixed-period
conventional six month recall interval.
Fixed-period recall intervals
Patient participants allocated to the conventional six
month recall interval and extended 24 m recall interval
groups will attend their dentist at the scheduled time in-
tervals for a ‘routine’ dental check-up. The content of this
check-up will remain as per current practice. A recognised
definition of a ‘traditional’ NHS dental check-up is clinical
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examination, advice, charting including monitoring of
periodontal status and report [4]. For participants allocated
to the fixed-period recall groups dentists will provide rou-
tine care using their current system for examination, record
keeping and providing advice.
Risk-based recall
Participants allocated to the risk-based recall interval
group will attend their dentist at time intervals deter-
mined by the evidence-based process outlined in the
“2004 NICE guideline on Dental Recall” [2]. The essen-
tial steps of the procedure and the risk factors collected
at recall examinations are outlined (from the Guideline)
in the two figures below (Fig. 1).
The recommended stages in establishing the appropri-
ate recall interval are:
1. Establishing the Age Range – establishing the
individual patient’s age. In the case of this trial all
patients will be adults of 18 years of age or more.
2. Consideration of Risk Variables – identification
of the pertinent risk and protective factors present
for each patient from the checklist and the
Comprehensive Oral Health Examination, leading
to the evaluation of the impact of these factors in
the context of the patient’s past levels of oral health
and current disease experience and then,
consideration of a likely range of recall intervals.
3. Integration and Prediction of Recall Need - use
of all of the information obtained by the dental
team in order to predict the potential level of threat
to maintaining oral health and controlling disease
for this patient and, from this, to judge the most
appropriate next recall interval.
4. Discussion – to explicitly discuss the
recommended recall interval with the patient,
explain the influencing factors in setting the recall
and record the agreed interval (or any reason given
by a patient in disagreement).
5. Review - at each check-up review (oral health
review), the appropriateness of the just-concluded
interval is reviewed by dentist and patient and the
recall interval is reset according to the experience
from the last period along with any change in the risk
and protective variables identified at re-examination.
The frequency of recall interval appropriate for an individ-
ual patient will depend on the likelihood that specific dis-
eases or conditions may develop or may progress beyond the
control of secondary prevention. The guidance (built on ex-
tensive consensus methods and the limited evidence avail-
able) indicated that the recall interval range should vary from
three to 24 m, according to risk. Training in assessment of
relevant risk and protective factors to consider when allocat-
ing a recall interval will be provided by means of a specific-
ally developed online training package based on the relevant
NICE Guideline. Online training in allocation of risk-based
recall will be carried out annually.
It is anticipated that by carrying out a comprehensive
history and oral examination the dentist will be better
informed to provide an accurate risk assessment and
Fig. 1 The process of recall interval selection
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more appropriate preventive and interventive treatment
recommendations leading to improvements in maintain-
ing oral health, in oral health related quality of life and
will result in less dental anxiety for the patient.
Recall strategy allocation
Prior to randomisation, all patient participants will be
clinically examined by their dentist to determine suitability
for randomisation to the 24 m recall arm. A detailed risk
assessment is not part of this suitability examination and
the decision made will be based on current practice, with
routine examination criteria and record keeping.
Randomisation will be organised within two strata de-
pending on the recruited participant’s suitability to enter
the 24 m arm:
1) Twenty-four month recall versus risk-based recall
versus six month recall;
2) Risk-based recall versus six month recall.
Randomisation to trial arms will be carried out using the
automated central randomisation service at the Centre for
Healthcare Randomised Trials (CHaRT) at the University
of Aberdeen, with 24 h access by telephone. Allocation will
take place after the suitability examination. Eligible partici-
pants will be randomised in equal proportions within each
of the two strata according to a minimisation algorithm in-
cluding dentist, age, filled teeth - FT (FT ≤ 8 or FT > 8 [8])
and absence of gingival bleeding on probing. There will be
separate, identical algorithms for the two strata. The design
is summarised in the graphic below (Fig. 2).
Study recruitment and allocation
Identifying and recruiting dentists
We are aiming to recruit 50 general dental practitioners
from across the UK, including dentists in England, Scotland,
Wales and Northern Ireland, representing a cross-section of
practitioners in terms of urban/rural area, community-level
socio-demographics, and fluoridated or non-fluoridated
communities. It is a requirement that all recruited dentists
provide some NHS dental services for adults.
Dentists will be recruited to the trial through local research
networks, advertising in the dental press, and trial team at-
tendance at research network meetings. The Trial Office in
Dundee (TOD) will send potential dentist participants an
invitation letter, describing the study and interested dentists
invited to a local information and recruitment session.
Identifying and recruiting patients
Recruitment of patient participants will be achieved
through standard procedures and agreements for pri-
mary care research in the four nations. In Scotland
co-ordinators from the Scottish Primary Care Research
Network (SPCRN) will assist practice staff managing
previously scheduled appointments, by including Patient
Information Leaflets and an invitation to participate, in
the appointment letters. In England, Wales and North-
ern Ireland appropriate regional Comprehensive Local
Research Networks (CLRNs) will provide the identical
service. The TOD will not have access to any data prior
to the participant consenting to take part in the trial. At
this stage, those who clearly express no interest in taking
part will be sent an alternative check-up appointment to
see their dentist. More than one dentist per practice can
recruit participants into the trial. At the recruitment ap-
pointment the dentist will discuss the trial with the po-
tential participants and answer any questions. Those
who state they do not wish to take part will then receive
their check-up as normal. Eligibility of those who ex-
press an interest in taking part will be confirmed against
the trial inclusion and exclusion criteria. Those who are
eligible will be consented to the trial by their dentist.
The dentist will then examine the patient participant for
suitability for randomisation to the 24 m arm.
Fig. 2 Study design
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Inclusion criteria
Adult patients (≥ 18 years of age) who:
 Are dentate
 Have visited their dentist in the previous two years
 Receive their dental care as an NHS patient
Exclusion criteria
 Patients who have a medical condition indicating
increased risk of bleeding
 Immuno-compromised patients
Outcome measures
Primary outcomes
Clinical
 Gingival inflammation/bleeding on probing at the
gingival margin
Patient centred
 Oral health-related quality of life (OHRQoL)
Secondary outcomes
Clinical
 Dental caries
 Periodontal pocket depth
 Calculus
 Preventive and interventive care
Patient centred
 Dental anxiety
 Oral health related knowledge, attitudes, and
behaviours
 Use of and reason for use of dental services
 Satisfaction with care
Service-providers
 Dentist attitude towards dental recall strategies
Economic outcomes
 NHS costs
 Patient incurred costs
 General population preferences, willingness to pay
 Net benefits (Benefits – costs)
 Generic Quality of Life, measured using the EQ-5D-3 L
 Quality adjusted life years (QALYs)
 Incremental cost per QALY gained
There are two primary outcomes: the primary clinical
outcome is periodontal disease as measured by gingival
bleeding, and the primary patient centred outcome is
oral health-related quality of life as measured by the
Oral Health Impact Profile-14 (OHIP-14). These are the
outcomes that the study is powered at 80% to detect
meaningful changes. Other measures are collected as
secondary outcomes. Given the complex intervention
and the unknown correlation between the two different
dimensions of the study (patient and clinical), the study
will not correct the p-value for multiplicity of tests.
Data collection and processing
Participating dental practices will be expected to main-
tain a file of essential trial documentation which will be
provided by the TOD. This will include documenting
participant recall appointment attendance, dental treat-
ment required, and duration of recall appointments.
Collection of clinical outcome measures
Clinical outcomes will be measured at four years follow-up
by trained outcome assessors who are blinded to allocation.
Clinical outcome measures will be collected within four
months either side of the four year anniversary of partici-
pant randomisation. Gingival inflammation as bleeding will
be measured according to the Gingival Index of Loe [9] by
running a UNC periodontal probe circumferentially around
each tooth just within the gingival sulcus or pocket. After
30 s, bleeding will be recorded as being present or absent
on the buccal and lingual surfaces. The colour-coded UNC
periodontal probe will be used to measure periodontal
pocket depth and then the presence of calculus. Clinical
outcomes will be measured for all included teeth at six sites
per tooth [mesiobuccal, midbuccal, distobuccal, mesiolin-
gual, midlingual, and distolingual]. Third molar teeth will be
excluded from clinical examination, except where a second
molar tooth is absent and the third molar tooth has drifted
mesially to occupy the position of the second molar. The
sequence of scoring will be gingival inflammation, followed
by periodontal pocket depths and calculus. The periodontal
examination will take place first, then teeth brushed by the
examiner and caries examination carried out.
Measurements of caries experience at the enamel and
dentine threshold will be made using the validated Inter-
national Caries Detection and Assessment System (ICDAS)
[10–12] in the examination of clean and dry teeth aided by
a ball-ended explorer that is used to remove any remaining
plaque and debris and to check for surface contour, minor
cavitation or sealants. Third molar teeth will be excluded
from clinical examination, except where a second molar
tooth is absent and the third molar tooth has drifted mesi-
ally to occupy the position of the second molar. All surfaces
of all teeth excluding third molars will be examined and the
caries status recorded.
Throughout the four year trial follow-up period recruited
dentists will complete specially developed forms for each
participant, documenting dental treatment provided during
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the trial period, including scheduled and re-scheduled
check-up appointments. Details of preventive and interven-
tive treatment provided during the trial period will also be
accessed through the routinely collected data in all partici-
pating regions in the UK.
Collection of patient centred outcome measures
Patient centred outcomes will be measured at baseline and
annually by self-administered postal questionnaire. OHRQoL
will be measured using the OHIP-14 [13]. A standardised
measure of health status (EQ-5D-3 L) will be included to en-
able calculation of QALYs and conduct of the cost utility
analysis. Patient dental anxiety status will be measured using
recognised and validated psychological inventories [14, 15].
Annual patient questionnaires will also include questions re-
lating to patient oral health related knowledge, attitudes and
reported behaviours, satisfaction with dental care, and use
of and reasons for use of dental services throughout the
trial follow-up period.
Collection of economic measures
The costs of all dental treatment provided by NHS den-
tists to patients, including the costs of planned check-ups
are captured through the routinely collected data held by
Information Services Division (ISD) in Scotland, NHS In-
formation Centre, business services authority (BSA) in
England and Health and Social Care Business Services Or-
ganisation (HSCBSO) in Northern Ireland. Time, travel
and treatment costs associated with visits to the dentist
will be collected through baseline questionnaires adminis-
tered to trial participants on entry to the trial. Private den-
tal care and use of other NHS services for dental issues
are also collected by patient questionnaire.
Benefits to patients of the three intervention arms will
be measured in two ways. Public preferences will be elic-
ited regarding the value they place on different recall
strategies using a discrete choice experiment (DCE) (see
economic analysis). The DCE will be administered to a
separate sample of the public obtained from electoral
rolls over the course of the trial. Benefits are also mea-
sured in terms of QALYs (see above).
Analysis plan
Statistical analyses
The trial outcomes will be compared between the three
trial arms using generalized linear models adjusting for
the minimisation covariates and other covariates felt to
be of prognostic importance. Statistical significance will
be at the 2.5% level and corresponding confidence inter-
vals will be derived. All participants will remain in their
allocated group for analysis (intention to treat). Sub-
group analyses will explore the possible effect modifica-
tion of a number of factors including age, social class,
residence in a fluoridated area, dentist characteristics
(e.g. professional engagement, workplace stress) all using
stricter levels of statistical significance (p < 0.01). All trial
analyses will be according to a statistical analysis plan
that will be agreed in advance by the Trial Steering
Committee (TSC). The Data Monitoring and Ethics
Committee (DMEC) will meet at 9, 24, 36 and 48 months
to review progress and recommend any responses to di-
vergences from planned trial design.
Economic analyses
Estimation of costs
The costs will be estimated from both a NHS and a patient
participant perspective. The NHS costs include the cost of
the treatments provided by NHS dentists and primary care
and secondary use related to dental issues. The participant
incurred costs include time and travel costs for making
return visits to the dentist and payments for care received.
The quantity, unit cost and average cost per participant
will be reported. Regression analysis will be used to report
differences in costs between randomised groups, adjusting
for baseline participant characteristics (e.g. minimisation
variables). Bootstrapping is used to obtain confidence in-
tervals surrounding the average cost estimates.
Estimation of benefits
Two different approaches are used to estimate the benefits
of recall strategies: Willingness-to-Pay and QALYs. The re-
call strategies may vary in terms of health related outcomes
(e.g. caries) as well as non-health outcomes, such as level of
reassurance. The benefits of the recall strategies are there-
fore valued in monetary terms - willingness to pay (WTP)
value. A DCE will be used to provide a framework to
weight different process and outcomes measures. Discrete
Choice Experiments are increasingly used in the evaluation
of health care interventions to produce overall benefit
scores for treatments as well as examine the absolute and
relative importance of different outcomes considered as im-
portant. This approach has been adopted as measures such
as quality adjusted life years typically used in economic
evaluations may not be sufficient to capture the strength of
preferences for differences in the process and outcomes of
care associated with each intervention. A DCE is used to
estimate the WTP values for the different recall strategies.
The DCE presents individuals with a series of choices be-
tween different scenarios which vary in terms of frequency
of routine check-ups, experience of oral health problems,
and cost. The DCE will be administered to a nationally rep-
resentative sample of the UK general population.
The sample size required for the DCE reflects the need
for the sample to be larger than the number of inde-
pendent variables and provide an adequate sample for
each pre-determined subgroup e.g. dental attendance
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(regular, non-regular), non-smoker or current smoker;
socio-economic status (high, medium, low), (12 sub-
groups in total and 30–100 per subgroup). Allowing for
individuals to be present in a number of groups, the
questionnaire will be sent to 1000 individuals ([12 ×
50]x[100/60]). Appropriately specified logistic regression
analysis is used to model the preference as a function of
the attributes. Marginal rates of substitution between the
coefficients of the attributes and costs represent WTP.
Quality of Life is measured using the generic EQ-5D-3 L
instrument. EQ-5D-3 L is a standardised instrument for
use as a measure of health outcome. The EQ-5D-3 L scores
are measured at baseline, and annually as part of the patient
questionnaire. Quality Adjusted Life Years are estimated by
estimating the area under the lines that link the utility
scores obtained at the different time points. In case of any
baseline differences in the EQ-5D-3 L scores, regression
analysis is used where patient specific QALYs are modelled
as a function of the baseline EQ-5D-3 L score and arm of
the trial. The coefficient of arm of the trial represents the
QALY differences adjusted for baseline differences.
Estimation of cost-effectiveness
The economic analysis will assess whether fixed-period
24-month or risk-variable-adjusted length dental recall rep-
resents an efficient use of NHS resources compared to the
traditional fixed-period six-month recall. Cost-effectiveness
will be measured in terms of the incremental cost per
QALY gained and in terms of net benefits (cost-utility ana-
lysis and cost-benefit analysis).
The incremental cost per QALY is estimated by dividing
the difference in mean total costs by the difference in QALYs
between the arms of the Trial. This ratio can be compared to
the conventional threshold of £30,000 per QALY. Bootstrap-
ping is used to generate Cost-Effectiveness Acceptability
Curves (CEAC). The CEAC shows the probability that the
different recall strategies are cost-effective compared to usual
care at various thresholds of cost-effectiveness. The threshold
represents the decision-maker’s willingness to pay for an
additional QALY. The CEAC represents the joint uncertainty
surrounding the cost and QALY pairs.
The WTP values are mapped to recall strategy and
trial outcomes and are directly compared with the costs
to produce net benefits for each recall strategy. The re-
call strategy with the highest incremental net benefit
compared to six-monthly recall is the most efficient op-
tion. A net benefit curve is produced which shows the
probability of the net benefits being larger than different
potential thresholds.
Missing data
Two approaches will be used to deal with any missing data.
The data will first be analysed using complete cases only.
This may lead to biased and incorrect results if a relatively
large proportion is missing. Multiple imputation using
iterative chained equations is therefore also used to impute
missing values. Data are imputed at each time point based
on an iterative algorithm, imputing five datasets, adjusting
for baseline characteristics. Data will be predicatively mean
matched to fit within the range of the available data.
Sensitivity analysis
Univariate sensitivity analysis is used to examine the im-
pact of the discount rate, uncertainty surrounding the
unit cost data, missing data, centre-specific variation.
Sample size
An exploratory trial in a similar population reported
35% of gingival sites were bleeding on probing (standard
deviation of 25%) [16]. The Cochrane review of peri-
odontal instrumentation (PI) suggested that six monthly
PI versus no PI reduces bleeding sites by 15% [17]. The
recall interval would be expected to produce an effect
lower than this given that the majority of participants in
all arms will still receive PI at some time during follow
up. Assuming either risk-based versus 24 m or six month
versus 24 m could reduce/increase the proportion of sites
bleeding by 7.5%, a study with 235 in each arm could detect
such a difference with 90% power at 5% significance, and
likewise detect a difference of 0.3 of the standard deviation
of the OHIP-14 or any other global measure of OHRQoL.
For the caries clinical outcome, assuming a standard devi-
ation of 3.5 a study with 235 participants per arm could de-
tect a shift in white spots lesions (from 3.3 to 4.2) at 80%
power and 5% significance [18].
We can combine the two strata, without introducing bias,
to estimate this comparison. We anticipate smaller effect
sizes for the six month versus risk-based recall comparison
than six monthly versus 24 monthly given that many of the
participants in the risk-based group will be seen more fre-
quently than 24 m. A study with 750 participants in each
arm could detect a difference in bleeding scores of 4.5% at
least 90% power and 5% significance level, and likewise
detect a difference of 0.17 of the standard deviation of the
OHIP-14. For the caries clinical outcome, assuming a
standard deviation of 3.5 a study with 750 participants per
arm could detect a 20% relative shift in white spot lesions
from 3.3 to 3.9 at 90% power and 5% significance [18].
Although there is no reason to be concerned about con-
tamination effects in this trial or clustering by dentist, the
sample size has been conservatively estimated such that if
contamination occurred with 15% of the control participants
or the intra cluster correlation was 0.03, the study would still
have 80% power to detect the hypothesised changes in the
bleeding score. Our sample size calculations indicate we need
to randomise 705 participants to stratum 1 (235 in each
arm) and 1030 to stratum 2 (515 in each arm).
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Likely rate of loss to follow-up
In the power calculation we have assumed a loss to
follow-up for dentists of 10% based on the observed rates
of 12 and 9% in two recent large, multi-centre practice
based RCTs [19]. For patient participants it is anticipated
that loss to follow-up will be not more than 15% at 4 years.
This estimate is based on a practice based trial conducted
in North-West England where 79% of 4211 participants
were retained for a period of 5 years [20]. In a recent trial
conducted in a similar population 78% of participants
returned a follow-up postal questionnaire. In this trial we
anticipate a lower loss to follow-up because we will be
using a more intensive reminder system and will explore
the use of evidence based strategies to improve response.
Ethical considerations
The trial will be coordinated by TOD in the University of
Dundee and CHaRT in the University of Aberdeen – both
centres with experience of multicentre trials, cognisant of the
implications of research governance and other legal frame-
works for the conduct of trials. Informed signed consent will
be obtained from the trial participants who will be given suf-
ficient time to accept or decline involvement and are free to
withdraw from the study at any time. The design of the study
ensures that adults for whom a 24-month recall interval may
be detrimental are not put at risk of allocation to this group.
It will be made clear to participants and dentists that partici-
pants may attend at any time if there is a need for a dental
appointment between recall visits. No dental treatment in-
cluding referral to specialist services will be withheld from
participants as a result of taking part in the trial.
This is not classed as a trial of any investigational medi-
cinal products or procedures, and so does not come under
EU Clinical Trials Directive. We will continue to conduct
the study to the standards required by the NHS Univer-
sities Research Governance Framework as well as all other
applicable legal, ethical and regulatory requirements.
Data protection and archiving
Participants will be reassured that all data which are col-
lected during the course of the research will be kept
strictly confidential. All participants’ details will be anon-
ymised and stored on a database under the guidelines of
the 1998 Data Protection Act. The relevant research docu-
mentation will be archived at the University of Dundee for
at least five years after completion of the trial as required
by the applicable regulatory requirement(s).
Governance arrangements
Research Governance applies to everyone working in the
TOD and CHaRT. All research will therefore be con-
ducted within the appropriate legislative and regulatory
environment and in accordance with Good Clinical
Practice (GCP). All staff involved in the trial at the two
centres will have undertaken appropriate GCP training.
The two main groupings that contribute to the govern-
ance arrangements for this study are: an independent
Trial Steering Committee (TSC); and an independent
Data Monitoring Committee (DMC). The TSC includes
an independent Chairperson and other independent mem-
bers including a consumer representative/lay person. The
TSC will also comprise a selection of the co-applicants in-
cluding the joint Chief Investigators (Professor Pitts and
Professor Clarkson), and the trial statistician (Professor
Ramsay). There will only be two voting members drawn
from any of the co-applicants. The TSC will meet annually
throughout the course of the study. The Data Monitoring
and Ethics Committee will continue to report any recom-
mendations to the Chair of the TSC, meeting before the
TSC. The Trial Management Committee (TMC) will in-
clude all co-investigators and act in an advisory capacity.
The University of Dundee has agreed to act as spon-
sor. As such, the TOD will undertake to communicate
promptly and effectively with the sponsor to satisfy the
sponsor’s obligations on the authorisations, financing
and progress reporting of the trial are met.
Arrangements for day to day management of the trial
The trial will be co-ordinated from the TOD and will pro-
vide day to day support for the dental practices. CHaRT will
provide the database applications and IT programming for
the TOD, host the randomisation system and take responsi-
bility for all statistical aspects of the trial. The TOD will be
responsible for transacting the randomisation, collecting all
trial data, co-ordination of patient participant follow-up ap-
pointments, and data processing. The dental practice will
be responsible for recruiting participants (including initiat-
ing the randomisation call). An Operations Management
Committee, led by the Trial Manager, will meet weekly in
the early stages at the TOD to ensure smooth running of
the trial, trouble-shooting issues as they arise and ensuring
consistency of action across the participating centres.
CHaRT staff will join this group as required, weekly by tele-
conference and in person every 4–6 weeks. These face to
face meetings will become less frequent as the trial pro-
gresses successfully, and increase again in frequency as the
trial enters its closedown phase. The TMC will meet annu-
ally and be chaired by the Chief Investigators and include
all the co-investigators and key members of the TOD and
CHaRT. Their remit will be to oversee the progress of the
trial in an advisory capacity.
Publication
The results of the study will be reported first to study
collaborators. A main report will be drafted by the pro-
ject management group and circulated to all clinical
co-ordinators for comment before a final version is con-
sidered for publication by the TSC.
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Dissemination
The results of this trial will be disseminated widely and ac-
tively through professional, primary care, public and scien-
tific routes. Results will be communicated directly to all
participating dental practices and an open workshop will
be held with them discussing the next steps in getting the
findings of the study to influence clinical practice. The
trial results will be used to inform policy (through targeted
feedback to all of the UK Health Departments and the
British Association for the Study of Community Dentistry
and its Consultants in Dental Public Health Group); prac-
tice (through specific communications to NICE, the
British Dental Association and the Faculty of General
Dental Practice (UK)); the public (through INVOLVE and
patient organisations) as well as with dental education and
training through a range of communications to postgradu-
ate dental Deans and the undergraduate dental schools.
Given the current dearth of directly applicable evidence
around this important research question it is anticipated
that the impact of this trial will be felt at the International
level as well as closer to home (specific presentations will
be made to the International Association for Dental
Research and its Evidence Based Dentistry Network as
well as to organisations such as the European Association
for Dental Public Health and related European specialty
societies for research and practice).
Discussion
The INTERVAL Dental Recalls Trial is an NIHR HTA
funded trial being undertaken across the UK and will begin
to address the lack of high quality evidence to aide dental
practitioners, patients and policy makers in their decision
making regarding allocation of dental recall intervals.
In order to ensure the results of this trial are widely applic-
able, the geographical areas that are included in the INTER-
VAL Trial have been selected to yield a cross-section of
practices, operating in a range of different environments and
circumstances (e.g. high, middle or low income communities,
fluoridation status, rural and urban, method of remuneration
of GDPs (capitation and fee for item of service or a banded
payment system based on Units of Dental Activity (UDA)).
The study team is multidisciplinary and broad-based,
which will ensure that whilst the trial design and conduct is
of the highest standard, it remains practical and pragmatic
at all times. We expect the INTERVAL Trial to provide evi-
dence that will benefit the future dental care, improve out-
comes of treatment and inform decision making by policy
makers, clinicians and patients, within and out with the UK
National Health Service.
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